title: Prostaglandin I2 versus prostaglandin E2 in dogs with and without low cardiac output. Differential effects on renal function.
abstract: Exogenous prostaglandin (PG) administration has been proposed as a vasodilator therapy for heart failure patients. The effects of this therapy on renal function have not been well studied in this disorder. Therefore, we investigated the renal effects of the PGI2 analog iloprost in comparison to PGE2 in 12 conscious dogs before and after induction of a low cardiac output state by rapid right ventricular pacing (250 beats/min for 10 days). In healthy dogs, 5 to 150 ng/kg/min iloprost increased renal plasma flow without affecting glomerular filtration rate and decreased urine flow without affecting natriuresis. PGE2 at the same dosages increased renal plasma flow and urinary sodium excretion without changing the glomerular filtration rate or amount of diuresis. In dogs with low cardiac output and lower basal renal plasma flow, iloprost did not change renal plasma flow, but decreased glomerular filtration rate and filtration fraction. In these animals, PGE2 insignificantly increased renal plasma flow, but significantly augmented urine flow and sodium excretion. We therefore conclude that in an experimental low cardiac output state, PGI2 may cause a deterioration of renal function. In contrast, PGE2 induces natriuresis and diuresis despite an attenuated increase in renal plasma flow. Thus, PGE2 promises to exert a more favorable profile of renal effects in heart failure therapy.
authors.affiliation: Medizinische Universitätsklinik, Würzburg, Germany.
authors.forename: D
authors.initials: D
authors.lastname: Elsner
authors.forename: A
authors.initials: A
authors.lastname: Müntze
authors.forename: E P
authors.initials: EP
authors.lastname: Kromer
authors.forename: G A
authors.initials: GA
authors.lastname: Riegger
mesh_terms: D000818:Animals; D002303:Cardiac Output, Low / Q000188:drug therapy* / Q000503:physiopathology; D015232:Dinoprostone / Q000008:administration & dosage / Q000627:therapeutic use*; D004285:Dogs; D011464:Epoprostenol / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects / Q000502:physiology; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects / Q000502:physiology*; D012964:Sodium / Q000652:urine; D014664:Vasodilation / Q000187:drug effects / Q000502:physiology
chemical_list: D012964:Sodium; D011464:Epoprostenol; D015232:Dinoprostone